Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Meihua International Medical Technologies Co Debt-to-EBITDA?
Meihua International Medical Technologies CoMHUAF 59 Debt-to-EBITDA is 0.75 as of Dec. 2025, which is 60% above its 10-year median of 0.47. GuruFocus rates MHUAF with a GF Score™ of 59/100 and a GF Value™ of $26.50 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 466 Medical Devices & Instruments companies, Meihua International Medical Technologies Co ranks better than 60.52% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
MHUAF's Debt-to-EBITDA is ranked better than 60.52% of 466
companies
in the Medical Devices & Instruments industry
Industry Median: 1.585
vs MHUAF: 0.88
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Meihua International Medical Technologies Co Debt-to-EBITDA Related Terms
Meihua International Medical Technologies Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Meihua International Medical Technologies Co Debt-to-EBITDA Chart
Meihua International Medical Technologies Co Annual Data
MHUAF vs CUPR, LUCY, NXGL: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Meihua International Medical Technologies Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Meihua International Medical Technologies Co Debt-to-EBITDA vs Medical Devices & Instruments Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Meihua International Medical Technologies Co (MHUAF) has a Debt-to-EBITDA of 0.75 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Meihua International Medical Technologies Co. This is 60% above median its historical median of 0.47. Over the past decade, Meihua International Medical Technologies Co's Debt-to-EBITDA has ranged from 0.13 to 0.88. According to the industry distribution chart, Meihua International Medical Technologies Co ranks #184 out of 466 companies in the Medical Devices & Instruments industry, placing it in the top 39.5%.
Is Meihua International Medical Technologies Co's Debt-to-EBITDA too high?
Meihua International Medical Technologies Co's current Debt-to-EBITDA of 0.75 is 60% above median its 10-year median of 0.47. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 0.88. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.59. Meihua International Medical Technologies Co's value of 0.75 is 52.7% below this industry median. Based on the distribution chart, Meihua International Medical Technologies Co ranks #184 out of 466 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Meihua International Medical Technologies Co has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Meihua International Medical Technologies Co's Debt-to-EBITDA compare to CUPR and LUCY?
According to the Medical Devices & Instruments industry distribution chart, Meihua International Medical Technologies Co ranks #184 out of 466 companies for Debt-to-EBITDA. This puts Meihua International Medical Technologies Co in the upper half of its industry. The industry median Debt-to-EBITDA is 1.59. Meihua International Medical Technologies Co's value of 0.75 is 52.7% below this benchmark. Historically, Meihua International Medical Technologies Co's own Debt-to-EBITDA has ranged from 0.13 to 0.88 over the past decade. While the company's 10-year median is 0.47 vs. the industry median of 1.59, Meihua International Medical Technologies Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.59, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Meihua International Medical Technologies Co's current Debt-to-EBITDA of 0.75 is 52.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Meihua International Medical Technologies Co. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Meihua International Medical Technologies Co's current Debt-to-EBITDA is 0.75, which is 60% above median its own 10-year median of 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Meihua International Medical Technologies Co stock overvalued right now?
Based on GuruFocus' analysis, Meihua International Medical Technologies Co (MHUAF) is currently considered Possible Value Trap. The stock's GF Value™ is $26.50, compared to a current price of $8.77 — trading 66.9% below its estimated fair value. The current Debt-to-EBITDA is 0.75, which is 60% above median its 10-year median of 0.47 and 52.7% below the Medical Devices & Instruments industry median of 1.59. Meihua International Medical Technologies Co's overall GF Score™ is 59/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Meihua International Medical Technologies Co (MHUAF), the current Debt-to-EBITDA is 0.75 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Meihua International Medical Technologies Co (MHUAF) Overvalued in 2026?
Based on GuruFocus' analysis, Meihua International Medical Technologies Co stock appears to be undervalued.
The current stock price of $8.77 is trading 66.9% below its estimated GF Value™ of $26.50.
GuruFocus considers Meihua International Medical Technologies Co to be Possible Value Trap.
Key valuation signals for MHUAF:
Debt-to-EBITDA: 0.75 (60% above median its 10-year median of 0.47)
GF Value™: $26.50 vs. price of $8.77 (66.9% below fair value)
Industry Position: 52.7% below the Medical Devices & Instruments median (#184 of 466)
No single metric tells the full story. See the MHUAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Meihua International Medical Technologies Co Ltd is engaged in providing disposable medical devices. It serves hospitals, pharmacies, medical institutions, and medical equipment companies. Its product offerings include a Disposable Medical mask, Disposable ID Bracelet, Disposable Artificial Anal bag, Disposable Catheter, and Electonic pump among others.
59GF Score
Get the complete analysis for MHUAF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MHUAF has been successfully added to your 
